Pneumonia is responsible for a tremendous burden of disease worldwide. In the U.S., it is a leading cause of death due to infection, especially for those of advanced age. For survivors, pneumonia’s lingering effects such as reduced lung function, scarring, and new or worsened respiratory issues like asthma or COPD may accelerate unhealthy aging. While pneumonia is fundamentally a disease of the lung tissue characterized by inflammation and alveolar damage, medical science has historically relied on symptoms, imaging (X-rays), and microbiological cultures (microbe-directed) to classify the disease, rather than analyzing the specific cellular damage and structural changes in the lungs (histopathology) to create personalized treatment subgroups (subphenotyping).
Continue Reading this article here
